Far Infrared Irradiation for Management and Treating of Parkinson's Disease (PD)
Primary Purpose
Parkinson's Disease
Status
Unknown status
Phase
Phase 1
Locations
Canada
Study Type
Interventional
Intervention
Far Infrared Radiation (5μm to 20μm wavelength)
Sponsored by
About this trial
This is an interventional treatment trial for Parkinson's Disease focused on measuring Idiopathic Parkinson's Disease, Lewy Body Parkinson's Disease, Paralysis Agitans, Parkinson's Disease, Idiopathic, Parkinson's Disease, Lewy Body, Primary Parkinsonism
Eligibility Criteria
Inclusion Criteria:
- People with Parkinson's Disease
Exclusion Criteria:
- None
Sites / Locations
- The Centre for Incurable Diseases
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
1
Arm Description
Radiation: Far Infrared Radiation (5μm to 20μm wavelength)
Outcomes
Primary Outcome Measures
Cure for PD
Secondary Outcome Measures
Rehabilitation of PD Patients
Full Information
NCT ID
NCT00674895
First Posted
May 6, 2008
Last Updated
January 2, 2009
Sponsor
GAAD Medical Research Institute Inc.
1. Study Identification
Unique Protocol Identification Number
NCT00674895
Brief Title
Far Infrared Irradiation for Management and Treating of Parkinson's Disease (PD)
Official Title
Phase 1 Study to Determine the Efficacy of Using Far Infrared Radiation for Control and Treatment of Parkinson's Disease.
Study Type
Interventional
2. Study Status
Record Verification Date
January 2009
Overall Recruitment Status
Unknown status
Study Start Date
May 2008 (undefined)
Primary Completion Date
May 2010 (Anticipated)
Study Completion Date
June 2010 (Anticipated)
3. Sponsor/Collaborators
Name of the Sponsor
GAAD Medical Research Institute Inc.
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
Parkinson's disease (PD) is a degenerative disorder of the central nervous system that often impairs the sufferer's motor skills and speech. This study will investigate the use of far infrared radiation to manage, control and treat PD.
Detailed Description
Parkinson's disease belongs to a group of conditions called movement disorders. It is characterized by muscle rigidity, tremor, a slowing of physical movement and, in extreme cases, a loss of physical movement. The primary symptoms are the results of decreased stimulation of the motor cortex by the basal ganglia, normally caused by the insufficient formation and action of dopamine, which is produced in the dopaminergic neurons of the brain. PD is both chronic and progressive.
Observations from our research studies indicate that, far infrared rays provide energy to the body, improve the autonomic functions of the nervous system, restore the functions of the endocrine system, strengthen the immune system, improve blood circulation and increase the level of oxygen in the cells and promote the regeneration of muscle cells, nerves and brain cells.
It is hereby postulated that irradiation using far infrared, with wavelength between 5 to 20 microns, of the central nervous system, the endocrine system and the whole body could prevent, control, manage or possibly lead to complete rehabilitation of people who have PD.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Parkinson's Disease
Keywords
Idiopathic Parkinson's Disease, Lewy Body Parkinson's Disease, Paralysis Agitans, Parkinson's Disease, Idiopathic, Parkinson's Disease, Lewy Body, Primary Parkinsonism
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 1
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
10 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
1
Arm Type
Experimental
Arm Description
Radiation: Far Infrared Radiation (5μm to 20μm wavelength)
Intervention Type
Radiation
Intervention Name(s)
Far Infrared Radiation (5μm to 20μm wavelength)
Other Intervention Name(s)
Far Infrared Radiation
Intervention Description
Radiation: Far Infrared Radiation (5μm to 20μm wavelength). Far Infrared radiation for 30 to 40 minutes per treatment session.
Primary Outcome Measure Information:
Title
Cure for PD
Time Frame
2 years
Secondary Outcome Measure Information:
Title
Rehabilitation of PD Patients
Time Frame
2 Years
10. Eligibility
Sex
All
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
People with Parkinson's Disease
Exclusion Criteria:
None
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Ken Nedd, M.D.
Organizational Affiliation
GAAD Medical Research Institute Inc.
Official's Role
Principal Investigator
Facility Information:
Facility Name
The Centre for Incurable Diseases
City
Toronto
State/Province
Ontario
ZIP/Postal Code
M4V 1L5
Country
Canada
12. IPD Sharing Statement
Learn more about this trial
Far Infrared Irradiation for Management and Treating of Parkinson's Disease (PD)
We'll reach out to this number within 24 hrs